Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embrella CE marks blood clot deflector

This article was originally published in Clinica

Executive Summary

Embrella Cardiovascular has CE marked its Embrella Embolic Deflector for sale in Europe. The device acts as a protective shield, deflecting blood clots from arteries that lead to the head and stopping them from blocking blood vessels in the brain. This should decrease the incidence of ischaemic stroke during procedures such as transcatheter aortic valve implantation (TAVI), which can dislodge debris and calcific particles that are found in diseased arteries. TAVI is approved in Europe for patients with severe aortic stenosis, and Embrella (Wayne, Pennsylvania) expects the global market to grow from $200m in 2009 to over $1.7bn in 2015. The company hopes its device will become the standard of care in all TAVI procedures.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel